Mesenchymal stem cell therapy - NextCell Pharma

Drug Profile

Mesenchymal stem cell therapy - NextCell Pharma

Alternative Names: ProTrans

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NextCell Pharma
  • Class Cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Type 1 diabetes mellitus
  • Research Renal transplant rejection

Most Recent Events

  • 12 Oct 2017 Phase-I/II clinical trials in Type-1 diabetes mellitus in Sweden (IV) (EudraCT2017-002766-50)
  • 05 Sep 2017 NextCell Pharma receives approval from ethics committee to initiate a phase I/II trial for Type-1diabetes mellitus
  • 24 Jul 2017 NextCell Pharma submits an IND application the Swedish Medical Products Agency for a phase I/II trial for Type-1 diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top